Prospect: information for the user
COMBIGAN 2 mg/ml + 5 mg/ml eye drops in solution.
Brimonidine tartrate and timolol
Read this prospect carefully before starting to use this medicinebecause it contains important information for you.
|
1. What is COMBIGAN and for what it is used
2. What you need to know before starting to use COMBIGAN
3. How to use COMBIGAN
4. Possible adverse effects
5. Storage of COMBIGAN
6. Contents of the package and additional information
COMBIGANis an eye drop used for the control of glaucoma. It contains two medications (brimonidine and timolol) that both reduce elevated eye pressure. Brimonidine belongs to a group of medications called alpha-2 adrenergic receptor agonists. Timolol belongs to a group of medications called beta-blockers.
COMBIGANis prescribed to reduce elevated eye pressure inside the eye when the use of beta-blocker eye drops is not sufficient.
Your eye contains a clear watery liquid that nourishes the inside of the eye. Continuously, liquid is eliminated from the eye and new liquid is generated to replace it. If the liquid cannot exit the eye quickly enough, eye pressure increases and could, over time, damage your vision.COMBIGANacts by reducing the production of liquid and increasing the amount of liquid that exits. This reduces eye pressure while new liquid continues to be generated.
No useCOMBIGANeye drops in solution:
If you believe any of these points apply to you, do not useCOMBIGANuntil you have consulted with your doctor again.
Warnings and Precautions
Consult your doctor before starting to useCOMBIGAN,
Children and Adolescents
COMBIGANshould not be used in children under 2 years or generally in children between 2 and 17 years.
Other Medications and COMBIGAN
COMBIGAN may affect or be affected by other medications you are taking, including other eye drops for glaucoma treatment.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including medications for any other condition, even if not related to your eye problem, and even those acquired without a prescription.
There are a series of medications that may interfere with COMBIGAN, so it is very important to tell your doctor if you are taking:
If you change the dose of any of the medications you take or if you consume alcohol regularly, you must tell your doctor.
If you are to undergo anesthesia, you must tell your doctor or dentist that you are using COMBIGAN.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or intend to become pregnant, consult your doctor or pharmacist before using this medication.Do not use COMBIGANif you are pregnant unless your doctor considers it necessary.
Do not useCOMBIGANif you are breastfeeding. Timolol may pass into breast milk. Consult your doctor before using any medication during breastfeeding.
Driving and Operating Machinery
COMBIGANmay cause drowsiness, fatigue, or blurred vision in some patients.Do not drive or operate tools or machinery until the symptoms have disappeared. If you notice any problem, talk to your doctor.
Combigan contains benzalkonium chloride
This medication contains 0.25 mg of benzalkonium chloride in each 5 ml of solution, equivalent to 0.05 mg/ml.
Benzalkonium chloride may be absorbed by soft contact lenses, altering their color. Remove contact lenses before using this medication and wait 15 minutes before reinserting them.
Benzalkonium chloride may cause eye irritation, especially if you have dry eye or other corneal diseases (transparent layer of the front part of the eye). Consult your doctor if you feel a strange sensation, burning, or pain in the eye after using this medication.
COMBIGAN contains phosphates:
This medication contains 52.9 mg of phosphates in each ml of solution, equivalent to 10.58 mg/ml.
If you have severe corneal damage (the transparent layer of the front part of the eye), treatment with phosphates, in rare cases, may cause blurred vision due to calcium accumulation.
Follow exactly the administration instructions of this medication as indicated by your doctor.In case of doubt, consult your doctor or pharmacist again. COMBIGAN should not be used in children under 2 years and its habitual use is not recommended in children and adolescents (between 2 and 17 years).
The recommended dose is one drop ofCOMBIGAN, twice a day, with a 12-hour interval.Do not change the dose or stop applying it without consulting your doctor.
If you useCOMBIGANwith other eye drops, wait at least five minutes between its application and the application of the other eye drops.
Instructions for use
Do not use the container if the safety seal is broken when opening the product for the first time.
Wash your hands before opening the container.Incline your head backward and look up.
If the drop falls outside the eye, try again.
To help prevent infections, avoid letting the tip of the container touch the eye, or any other surface. Close the container immediately after use.
If you use moreCOMBIGANthan you should
Adults
If you use more COMBIGAN than you should, it is unlikely to cause any harm. Put the next drop at the usual time. If you are concerned, talk to your doctor or pharmacist.
Babies and children
Some cases of overdose have been reported in babies and children treated with brimonidine (one of the components ofCOMBIGAN) as part of the treatment for glaucoma. Drowsiness, flaccidity, low body temperature, pallor, and respiratory difficulties were observed. If this occurs, contact your doctor immediately.
Adults and children
In case of accidental ingestion, contact your doctor.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91-562 04 20.
If you forgot to useCOMBIGAN,
If you forgot to useCOMBIGAN,use one drop in each eye that needs treatment as soon as you remember, and then return to your regular routine.Do not duplicate the dose to compensate for the missed doses.
If you interrupt the treatment withCOMBIGAN
ForCOMBIGANto work properly, you must use it every day.
If you have any further questions about the use of this product, ask your doctor or pharmacist.
If you notice any of the following side effects, please contact your doctor immediately:
The following side effects may be observed with COMBIGAN:
Affecting the eye
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Unknown frequency (frequency cannot be estimated from available data):
Affecting the body:
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Unknown frequency (frequency cannot be estimated from available data):
Some of these effects may be due to an allergic reaction to one of the components of the product.
Additional adverse reactions have been observed with brimonidine or timolol, and therefore may occur with COMBIGAN.
The following adverse reactions have been observed in addition to brimonidine:
Like any other medication applied to the eyes, COMBIGAN (brimonidine/timolol) is absorbed into the blood. The absorption of timolol, a beta-blocker component of COMBIGAN, may cause adverse reactions similar to those observed with intravenous and/or oral beta-blockers. The incidence of adverse reactions after topical ocular administration is lower than with oral or injected medications.
The following adverse reactions have been observed with the use of beta-blockers to treat eye diseases:
Other adverse effects reported with eye drops containing phosphate:
If you suffer from severe damage to the cornea (the transparent layer at the front of the eye), treatment with phosphates, in very rare cases, may cause blurry vision due to calcium accumulation.
Reporting of adverse effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use:https://www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Store the container in the outer packaging to protect it from light.
Do not use more than one container at the same time.
Do not use this medication after the expiration date that appears on the box and on the container after EXP. The expiration date is the last day of the month indicated.
You must discard the container four weeks after opening it for the first time, even if there are still some drops left.This will help prevent infections.To help you remember, write the date you opened it in the corresponding space on the box.
Medications should not be thrown away through drains or in the trash.Deposit the containers and medications you do not need in the SIGRE collection point at the pharmacy.In case of doubtask your pharmacist how to dispose of the containers and medications you do not need. By doing so, you will help protect the environment.
Composition of COMBIGAN
Appearance of COMBIGAN and contents of the package
COMBIGAN is a clear, slightly yellowish-green solution in a plastic bottle with a screw cap. Each bottle is filled to approximately half and contains 5 ml of solution. There are available boxes containing 1 or 3 bottles. Some bottle sizes may only be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
AbbVie Spain, S.L.U.
Avenida de Burgos 91,
28050 Madrid
Spain
Responsible for manufacturing:
Allergan Pharmaceuticals Ireland
Castlebar Road
Westport, Co Mayo
Ireland
This medicine is authorized in the member states of the European Economic Area with the following names:
Austria | Combigan 2 mg/ml + 5 mg/ml eye drops |
Belgium | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Bulgaria | ???????? 2 mg/ml + 5 mg/ml eye drops, solution Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Czech Republic | COMBIGAN 2mg/ml + 5 mg/ml eye drops, solution |
Croatia | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Denmark | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Estonia | Combigan, 2 mg/5 mg/ml eye drops, solution |
Finland | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
France | COMBIGAN 2 mg/ml + 5 mg/ml, eye drops in solution |
Germany | Combigan 2 mg/ml + 5 mg/ml eye drops |
Greece | COMBIGAN eye drops, solution, (0.2 + 0.5)% |
Hungary | COMBIGAN 2 mg/ml+5 mg/ml eye drops |
Iceland | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Ireland | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Italy | COMBIGAN 2 mg/ml + 5 mg/mleye drops, solution |
Latvia | Combigan2 mg/5 mg/ml eye drops, solution |
Lithuania | Combigan 2mg/5mg/ml eye drops (solution) |
Luxembourg | Combigan 2 mg/ml + 5 mg/ml, eye drops in solution |
Netherlands | Combigan 2 mg/ml + 5 mg/ml, eye drops, solution |
Norway | Combigan 2 mg/ml + 5mg/ml eye drops, solution |
Poland | Combigan eye drops, solution, 2 mg/ml + 5 mg/ml |
Portugal | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Romania | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Slovakia | COMBIGAN 2 mg/ml + 5 mg/ml eye drops, solution |
Slovenia | COMBIGAN 2 mg/ml + 5 mg/ml eye drops, solution |
Spain | Combigan 2mg/ml + 5 mg/ml eye drops, solution |
Sweden | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
United Kingdom | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Last review date of this leaflet: 11/ 2020
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
The average price of Combigan 2 mg/ml + 5 mg/ml colirio en solucion in July, 2025 is around 15.67 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.